JAK2-IN-7 , CAS No.2593402-36-7

CAS: 2593402-36-7 Cat. No.: J647723 Formula: C₂₆H₃₃N₇O Molecular Weight: 459.59

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Overview

JAK2-IN-7 is a selective JAK2 inhibitor with IC 50 s of 3, 11.7, and 41 nM for JAK2 , SET-2, and Ba/F3 V617F cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1 , JAK3 , FLT3 . JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cell apoptosis . Antitumor activities

In Vitro

JAK2-IN-7 (compound 13ac) (0-1000 nM; 2 hours) inhibits JAK2 and STAT5 phosphorylation in a dose-dependent manner in SET-2 and Ba/F3-JAK2 V617F cells. JAK2-IN-7 (10-160 nM; 24 hours) induces cell arrest in the G0/G1 phase. JAK2-IN-7 (0.05-1.6 μM; 2 hours) induces apoptosis in SET-2 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Cycle AnalysisCell Line: SET-2 cells Concentration: 10-160 nM Incubation Time: 24 hours Result: Induced cell arrest in the G0/G1 phase in a concentration-dependent manner. Apoptosis AnalysisCell Line: SET-2 cells Concentration: 0.05-1.6 μM Incubation Time: 2 hours Result: Induced apoptosis in SET-2 cells.

In Vivo

JAK2-IN-7 (15-60 mg/kg; p.o.; daily for 16 days) shows potent in vivo antitumor efficacy with 82.3% tumor growth inhibition in the SET-2 xenograft model . JAK2-IN-7 (30-60 mg/kg; p.o.; q.d. for 16 day) significantly ameliorates the disease symptoms in a Ba/F3-JAK2V617F allograft model, with 77.1% normalization of spleen weight, which was more potent than Ruxolitinib . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: SET-2 cell-inoculated xenograft NOD/SCID mouse model Dosage: 15, 30, and 60 mg/kg Administration: Orally daily for 16 days Result: Exhibited a significant tumor growth inhibition of 82.3% without obvious weight change.

Form:Solid

IC50& Target:JAK1 42 nM (IC 50 ) JAK2 3 nM (IC 50 ) JAK3 94 nM (IC 50 ) Tyk2 75 nM (IC 50 ) FLT3 62 nM (IC 50 )

Specifications

Biochemical and Physiological Mechanisms

JAK2-IN-7 is a selective JAK2 inhibitor with IC 50 s of 3, 11.7, and 41 nM for JAK2 , SET-2, and Ba/F3 V617F cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1 , JAK3 , FLT3 . JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

This product requires cold chain shipping. Ground and other economy services are not available.

Action Type

INHIBITOR

Names and Identifiers

Molecular Weight

459.59

Chemical and Physical Properties

• Solubility: DMSO : 250 mg/mL (543.96 mM; Need ultrasonic)

Application Protocols

No manufacturer-validated protocols are supplied for this product.

General starting points (for small-molecule JAK-pathway probes)

• DMSO stock: Prepare 10–20 mM in anhydrous DMSO. Filter (0.22 µm PTFE) if particulates are visible.
• Enzyme assay (example framework):
  • Buffer: 50 mM HEPES pH 7.5, 10 mM MgCl2, 0.01% Tween-20, 1 mM DTT.
  • Enzyme/substrate: Recombinant JAK2 kinase domain and peptide/protein substrate per supplier guidance.
  • ATP: Near Km to reveal competitive inhibition.
  • Incubation: 25–30°C, 15–45 min; detect by ADP-Glo, radiometric filter binding, or phospho-specific antibody readouts.
• Cell assay (example framework):
  • Plate cells; pre-equilibrate at 37°C, 5% CO2.
  • Treat with serial dilutions (final DMSO ≤0.1–0.5%).
  • Stimulate relevant cytokine pathway if required; read pSTAT by Western/ELISA or reporter output.

These are literature-general templates. Optimize concentrations, times, and detection methods for your specific system. Always include appropriate positive/negative controls and vehicle controls.

Biological Roles

JAK2-IN-7 is designated as a research compound targeting the Janus kinase (JAK) pathway (based on name). Item-specific biochemical data are not supplied in this listing.

General pathway context (biochemistry; literature/general)

• JAK–STAT axis: JAK kinases (JAK1/2/3, TYK2) transduce cytokine and growth factor signals by phosphorylating STAT transcription factors following receptor engagement. JAK2 is particularly involved with receptors for erythropoietin, thrombopoietin, GM-CSF, and several interleukins.
• Catalytic mechanism: ATP-dependent phosphorylation on tyrosine residues of receptor tails and STATs; inhibitors typically compete with ATP at the kinase domain hinge region.
• Regulatory features: Pseudokinase domain (JH2) modulates JH1 catalytic activity; mutations (e.g., V617F in JAK2) alter activity and downstream STAT signaling in cells. This listing provides no mutation- or isoform-specific notes for JAK2-IN-7.

Use in research (general)

• Probe role: Small molecules named as JAK2 inhibitors are often used to interrogate cytokine-driven signaling, define pathway dependencies, and benchmark assay performance. For JAK2-IN-7, verify potency, selectivity across JAKs, and off-target profile from primary data before drawing conclusions.
• Assay suggestions: Time-course STAT phosphorylation assays (e.g., pSTAT5 Western/ELISA), reporter gene systems for STAT activity, and kinase panel profiling for selectivity.

Caution: No pharmacology, ADME, or toxicity data are provided here. Use exclusively for research in controlled laboratory settings.

Buffer Applications

This product is not a buffering agent. It does not define or maintain pH ranges in biochemical systems.

Practical notes (for using small-molecule probes in buffers)

• Vehicle: Prepare concentrated DMSO stock and dilute into assay buffer (e.g., HEPES, Tris, PBS) ensuring final DMSO is within assay-tolerated limits (commonly ≤0.1–0.5% v/v).
• Precipitation control: Add compound stock slowly to vigorously mixed, pre-warmed buffer; consider low levels of non-ionic surfactant if compatible.
• Adsorption: Use low-binding plastics or glass to minimize loss for hydrophobic compounds.

For buffer recipes or pH ranges, refer instead to dedicated buffering agents (HEPES, Tris, phosphate, MOPS).

Green Alternatives

Green chemistry considerations are generally aimed at solvents and bulk reagents. For a low-use, finished bioactive such as JAK2-IN-7, the principal opportunities are in solvent and process choices during handling and analysis rather than substitution of the active itself.

Greener handling strategies (general)

• Solvent minimization: Use the minimal DMSO concentration compatible with assay performance (e.g., ≤0.1% v/v in final wells) to reduce solvent burden.
• Aqueous-first approaches: If the compound permits, explore buffered aqueous vehicles with small co-solvent fractions, or cyclodextrin inclusion complexes, to lessen reliance on high-boiling polar aprotics.
• Analytical methods: Favor water/acetonitrile gradients over chlorinated solvents for LC, and use mass-directed collection to minimize repeats.
• Waste reduction: Aliquot to reduce thaw/refreeze and spoilage; consolidate wash steps; apply microscale assay formats.

Illustrative comparison (general; not item-specific)

• DMSO vs 2-(Hydroxypropyl)-β-cyclodextrin (HP-β-CD): DMSO offers broad solvency but higher environmental/worker exposure concerns; HP-β-CD can enable aqueous solubilization for some hydrophobes at the cost of added components and potential assay interference.

Note: Because the active molecule is the experimental variable, substitution with an alternative “greener” active is typically not applicable. Focus green efforts on formulation, assay design, and solvent selection.

Pharmaceutical Uses

No pharmaceutical or clinical use information is provided for this catalog item, and it is sold strictly for research use only.

Context (general, non-clinical)

• Formulation role: In research, small-molecule probes may be formulated for in vitro delivery (DMSO stocks) or preclinical exploration. This item has no pharmacopeial status or excipient role specified.
• Regulatory status: Not intended for human or veterinary use; not a drug substance or excipient per this listing.

Always consult institutional policies and relevant regulations before any non-laboratory handling. Do not use in diagnostics or therapeutic applications.

Physical Properties

Item-specific physical property data are not provided in this listing.

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Purity/Grade: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• Melting point / Boiling point: Not specified for this item; refer to CoA/Spec Sheet.
• Density / Refractive index: Not specified for this item; refer to CoA/Spec Sheet.
• Solubility (item-specific): Not specified for this item; refer to CoA/Spec Sheet.

General guidance for small-molecule kinase probes (literature/general)

• Solubility: Frequently soluble in polar aprotic organics (DMSO, DMF) and variably in alcohols (MeOH/EtOH). Aqueous solubility commonly enhanced with co-solvent (e.g., 0.1–1% DMSO), cyclodextrins, or pH adjustment if ionizable groups are present.
• LogP/cLogP: Many ATP-pocket binders are moderately lipophilic (cLogP ~2–5), but exact value is compound-dependent.
• Ionization: Compounds bearing basic heterocycles may show pKa in the 2–9 range for various centers; use potentiometric or UV-method pKa determination if formulation depends on ionization state.

Recommendations

• Determine solubility and stability in your intended assay buffer by small-scale tests (light/scatter, LC area counts). Avoid precipitation upon dilution from DMSO by premixing into warm buffer with vigorous mixing.
• For chromatographic method development, begin with a water/acetonitrile + 0.1% formic acid gradient and adjust based on retention/ionization.

Quality & Grades

• Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.

How to interpret quality information for small-molecule probes (general guidance)

• Purity reporting: Reputable probe listings report HPLC or UPLC purity (area %) at 220–254 nm and full spectral monitoring, plus orthogonal identity (1H NMR, HRMS). Impurity profiling near bioassay-relevant concentrations is recommended.
• Counterion/form: If provided as a salt or solvate, confirm stoichiometry and convert to free-base/acid equivalents when making stock solutions. This listing does not specify salt form.
• Stabilizers: None are indicated for this item. If stabilization is necessary (e.g., against oxidation or hydrolysis), this will appear on the CoA/SDS. Absent such notation, do not add stabilizers unless validated for your assay.
• UV background: For LC/UV detection or optical assays, verify baseline absorbance of vehicle controls across your detection wavelength; low-UV “HPLC grade” applies to solvents, not to actives like JAK2-IN-7.

Recommendations

• Request the latest CoA and, if available, lot-specific NMR/HRMS data prior to critical experiments.
• Upon receipt, perform an incoming QC check (rapid LC, purity at assay wavelength, identity confirmation) to ensure consistency with your internal methods.

Reaction & Applications

This product is a finished small-molecule research probe rather than a synthetic reagent. Consequently, it is not typically used as a solvent, reagent, or catalyst in preparative organic reactions.

Relevant applications (research use context)

• Biochemical assays: Tool compound for exploring JAK family signaling biochemistry in vitro (e.g., enzymatic kinase activity assays, binding assays). Specific activity/selectivity values for JAK2-IN-7 are not provided in this listing; consult primary literature if available.
• Cellular studies: Probe-based modulation of the JAK–STAT pathway in cell-based signaling assays, target engagement measurements (e.g., CETSA/DRAC/biotinylated analog pull-down), and pathway mapping. Optimize dosing and exposure empirically.
• Chemical biology: Potential use as a starting point for derivatization into affinity probes (photoaffinity tags, bioorthogonal handles) or for SAR campaigns; structural details for such modifications are not provided here.

Notes

• No named synthetic reactions are associated with the use of JAK2-IN-7 as a reagent.
• For mechanism-of-action or kinetic parameters, refer to peer-reviewed sources specific to this compound. Absent item-specific data, avoid assuming potency or selectivity profiles observed for other JAK2 inhibitors.

Reaction Conditions

Not applicable: JAK2-IN-7 is a research probe and is not intended as a reagent for chemical transformations.

Assay condition guidance (general for small-molecule kinase studies)

• Stock preparation: 10–50 mM in anhydrous DMSO; store aliquots at −20°C. Thaw just before use; avoid repeated freeze–thaw cycles.
• Biochemical kinase assays: Typical buffer systems include 20–50 mM HEPES, pH 7.4–7.5, 5–10 mM MgCl2, 0.01% Tween-20, 1–2 mM DTT; ATP near Km for the kinase tested. Incubations 10–60 min at 25–30°C. Optimize for your enzyme and detection method.
• Cell-based assays: Dose-response across ≥8 concentrations with half-log spacing; vehicle-matched controls; exposure 0.5–24 h depending on readout (e.g., pSTAT levels, reporter activity). Monitor cytotoxicity independently.
• Stability checks: Evaluate compound integrity over assay time by LC–MS in the exact matrix (buffer, media) used.

Note: The above are literature-general ranges for kinase assay development and are not item-specific specifications.

Safety & Handling

Safety data specific to this item are not included in the product data; consult the product SDS for authoritative information.

• GHS classification: Not specified for this item; refer to SDS.
• Signal word / H-statements / Pictograms: Not specified for this item; refer to SDS.

General laboratory safety for small-molecule research compounds

• Potential hazards: Irritation to skin/eyes/respiratory tract possible; some kinase inhibitors can show cytotoxicity in vitro. Handle as a hazardous laboratory chemical.
• PPE: Lab coat, safety glasses, and appropriate chemical-resistant gloves (e.g., nitrile). Use a certified chemical fume hood when weighing or preparing solutions.
• Avoid: Inhalation of dust/aerosols; contact with skin/eyes; ingestion. Prevent environmental release; collect waste in accordance with institutional and local regulations.
• First-aid overview (general):
  • Inhalation: Move to fresh air; seek medical attention if symptoms persist.
  • Skin contact: Wash with soap and water; remove contaminated clothing.
  • Eye contact: Rinse cautiously with water for several minutes; remove contact lenses if present and easy to do; seek medical advice if irritation persists.
  • Ingestion: Rinse mouth; seek medical attention.
• Handling tips: Minimize DMSO stock vial freeze–thaw cycles; aliquot upon receipt. Avoid cross-contamination between biological assay areas and synthetic/analytical benches.

Note: For research use only. Not for human or veterinary use.

Solvent Selection

Item-specific solubility data are not provided. The following are general, literature-based practices for small-molecule kinase probes.

• Primary stock solvent: DMSO is typically preferred due to high solvating power and assay compatibility at ≤0.1–0.5% v/v in final wells.
• Alternative solvents: DMF, NMP (strong polar aprotics); methanol or ethanol for less lipophilic scaffolds; acetonitrile for analytical injections. Water solubility may be limited without co-solvent or pH adjustment.
• Cosolvent strategies: Prepare concentrated DMSO stocks (e.g., 10–50 mM), then dilute into pre-warmed buffer with vigorous mixing to avoid precipitation. Use surfactant (e.g., 0.01% Tween-80) cautiously if permitted by assay.
• Buffer compatibility: Screen in common assay buffers (HEPES, Tris, PBS) and monitor for turbidity. Check adsorption to plastics; low-binding plates/tubes may reduce loss.
• Light/oxidation sensitivity: If the compound contains oxidizable heteroaromatics or anilines (unknown here), protect from light and air during long incubations; purge with inert gas if stability studies indicate degradation.

Quick comparison (general)

• DMSO: highest solvency; possible biological effects at >0.5%.
• DMF/NMP: strong solvency; use with caution in bioassays.
• EtOH/MeOH: more benign in cells but lower solvency; evaporate quickly in open systems.

Note: Verify exact solubility and stability for your lot; adjust solvent choices accordingly.

Storage & Reconstitution

Item-specific storage:

• Storage conditions: Store at −20°C (per product data).
• Shipping: Shipped in an ice chest with ice pads (per product data).

General reconstitution guidance for small-molecule probes

• Solvents: Reconstitute in anhydrous DMSO to prepare concentrated stocks (e.g., 10–50 mM). If aqueous use is required, dilute the DMSO stock into buffer with vigorous mixing; avoid direct addition of dry solid to aqueous media.
• Aliquoting: Dispense single-use aliquots to minimize freeze–thaw cycles. Protect from moisture and, if light-sensitive, from light (amber vials, foil wrap).
• Stability: Absent item-specific data, verify stability by periodic LC–MS or HPLC purity checks on stored stocks. Discard if precipitation, discoloration, or degradation is observed.
• Working solutions: Prepare fresh on the day of use. Maintain cold and protected from light during extended assays if stability is uncertain.

Notes

• Appearance, purity, and exact solubility are not specified for this item; consult the CoA/Spec Sheet.
• For research use only. Not for human or veterinary use.

Structure & Identity

JAK2-IN-7 is listed as a small-molecule research tool compound intended for kinase biology studies (JAK family). Item-specific structural identifiers are not provided in the product data.

• Product name: JAK2-IN-7 (research tool compound)
• CAS: 2593402-36-7
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
• Structural class (general): Small-molecule kinase inhibitor candidate; often features heteroaromatic cores, H-bond donor/acceptor motifs, and substituents tuned for ATP-site engagement (general medicinal chemistry knowledge; not item-specific).
• 2D structural description (general): Typical JAK inhibitors contain bicyclic/heteroaromatic scaffolds bearing amide/urea/aza-heterocycles to engage hinge residues and basic/polar functionalities to access the solvent front; exact features for JAK2-IN-7 are not provided here (literature-general).

Notes

• This catalog entry does not include stereochemical information or definitive functional group listing. Consult the Certificate of Analysis (CoA), structure file (SDF/Mol), or primary reference for precise identity and connectivity.
• Verify identity via NMR/HRMS/LC before use in critical assays when structure-sensitive outcomes are expected.

Synthetic Utility

JAK2-IN-7 is supplied as a finished bioactive probe rather than a building block. It is not typically used as a reagent or synthon in routine organic synthesis.

General guidance (if derivatization is intended)

• Probe derivatization: Chemical biology projects sometimes append linkers (alkynes/azides, biotin, photo-crosslinkers) to small-molecule inhibitors to generate affinity probes. Without a disclosed structure for JAK2-IN-7, suitable attachment vectors and stability considerations cannot be recommended here.
• Analytical characterization: Any semi-synthetic modifications should be tracked by LC–MS, 1H/13C NMR, and, where relevant, intact mass under soft ionization to confirm retention of the parent core.

Recommendation

• If synthetic use is desired, obtain the structural data (SDF/Mol and CoA) for this item, assess functional handle availability, and plan SAR-friendly transformations. Absent these details, treat JAK2-IN-7 as an endpoint compound, not a synthetic intermediate.

Target Specificity

Target specificity data (e.g., Ki/IC50 values, kinase panel selectivity) are not provided for this item.

• Antibody-style attributes (antigen, clone, isotype, species reactivity) do not apply to small molecules.
• For quantitative specificity against JAK isoforms (JAK1/2/3, TYK2) and off-target kinases, consult primary literature or conduct internal kinase panel profiling under your assay conditions.

Recommendation: Validate target engagement in your system via orthogonal assays (e.g., CETSA, NanoBRET target engagement, or downstream STAT phosphorylation changes) before drawing mechanism conclusions.

Frequently Asked Questions

How should this product be stored?

Store at ?20 °C. Freezer storage is required to maintain the specified shelf life.

How is this product shipped?

This product ships in an insulated container with ice pads. Unpack on arrival and transfer it to the storage condition stated above.

What are the CAS number, molecular formula and molecular weight?

The CAS Number is 2593402-36-7, the molecular formula is C26H33N7O, and the molecular weight is 459.59 g/mol.

What documentation is provided?

Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.